前瞻性、随机、蒙面、安慰剂对照多点Grapiprant临床研究,一个EP4前列腺素受体拮抗剂(PRA),与骨关节炎的狗。

文章的细节

引用

复制到剪贴板

Rausch-Derra L,许米,沃福德J,罗兹L

前瞻性、随机、蒙面、安慰剂对照多点Grapiprant临床研究,一个EP4前列腺素受体拮抗剂(PRA),与骨关节炎的狗。

J兽医实习生地中海。2016,(3):756 - 63。doi: 10.1111 / jvim.13948。Epub 2016年4月13日。

PubMed ID

27075237 (在PubMed

]

文摘

背景:本研究评估的有效性和安全性grapiprant治疗疼痛与骨关节炎(OA)的狗。假设/目标:Grapiprant将减轻疼痛的所有者和兽医的疼痛评估与OA的狗。另一个目标是评价grapiprant的安全。动物:二百八十五client-owned狗与OA登记和grapiprant或安慰剂治疗262例每组(N = 131)的可评价的有效性分析。方法:在这个前瞻性,随机,蒙面,安慰剂对照研究狗受到日常与grapiprant(2毫克/公斤)/ OS或安慰剂。业主完成了评估使用犬短暂痛苦0库存(CBPI)天,7、14、21、28。成功被定义为改善CBPI。兽医评估进行了筛选和14天、28天的评分。安全评估了体检,评价临床病理学结果,和所有者观察。结果:Grapiprant改善疼痛治疗与安慰剂相比在28天(31.3%和48.1分别治疗成功; P = .0315). The pain interference score (PIS) and pain severity score (PSS) improved in the grapiprant group compared to placebo (P = .0029 and 0.0022, respectively). Veterinary assessments were significantly better in the grapiprant-treated dogs (P = .0086). Grapiprant generally was well tolerated, but a higher percentage of treated dogs (17.02%) had occasional vomiting as compared to the placebo group (6.25%). CONCLUSIONS AND CLINICAL IMPORTANCE: Grapiprant is an effective treatment for alleviation of pain in dogs with OA, and represents a modality of treatment that may be better tolerated than current options.

DrugBank数据引用了这篇文章

药物

Grapiprant